Dermatomyositis: Clinical Trials

6 trials for Dermatomyositis, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 recruiting. 6 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	6	Recruiting 6
Phase 2	2	Recruiting 2

Follow Dermatomyositis: new trials by email Literature Review of Dermatomyositis trials Research Report on Dermatomyositis

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) ULSC (1.5 x 10^8 cells/dose), Placebo (no cells) - Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS	Phase 2 / Phase 3	Recruiting	Restem, LLC.	40	2026-01-06	2026-04-27
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies Dazukibart - Dermatomyositis, Polymyositis	Phase 3	Recruiting	Pfizer	211	2025-01-22	2026-08-25
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label) - Polymyositis, Dermatomyositis	Phase 3	Recruiting	AstraZeneca	240	2024-06-20	2026-09-24
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy CABA-201 following preconditioning with fludarabine and cyclophosphamide - Idiopathic Inflammatory Myopathy, Dermatomyositis	Phase 2 / Phase 3	Recruiting	Cabaletta Bio	74	2023-12-20	2026-10-15
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] PF-06823859, Placebo - Myositis	Phase 3	Recruiting	Pfizer	318	2023-05-20	2026-09-15
Baricitinib in Patients With Relapsing or naïve Dermatomyositis Baricitinib, Placebo - Dermatomyositis	Phase 3	Recruiting	Assistance Publique - Hôpitaux de Paris	62	2022-08-31	2026-06-02

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications